Company news

Amylyx Pharmaceuticals, Inc. news in 2023

Amylyx Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)

December 21, 2023

Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

December 3, 2023

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 28, 2023

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

November 27, 2023

RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND

November 26, 2023

Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 8, 2023

Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023

November 1, 2023

Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium

October 18, 2023

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

October 12, 2023

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control

October 9, 2023

Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France

October 4, 2023

RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting

October 1, 2023

Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 9, 2023

Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023

August 2, 2023

Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program

July 11, 2023

Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

June 22, 2023

Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS

June 14, 2023

Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

May 29, 2023

Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results

May 10, 2023

Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

May 4, 2023

Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America

April 19, 2023

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

April 12, 2023

Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

March 12, 2023

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

March 6, 2023

Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

February 6, 2023

Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS

February 1, 2023

Calls in 2023

Decks in 2023